Intellia Therapeutics Inc. (NASDAQ:NTLA) went up by 11.46% from its latest closing price compared to the recent 1-year high of $202.73. The company’s stock price has collected 24.02% of gains in the last five trading sessions. Barron’s reported on 06/28/21 that Intellia Stock Is Rocketing Because of a Gene-Editing Breakthrough
Is It Worth Investing in Intellia Therapeutics Inc. (NASDAQ :NTLA) Right Now?
Plus, the 36-month beta value for NTLA is at 2.06. Opinions of the stock are interesting as 19 analysts out of 24 who provided ratings for Intellia Therapeutics Inc. declared the stock was a “buy,” while 2 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $128.68, which is $77.92 above the current price. NTLA currently public float of 68.53M and currently shorts hold a 9.67% ratio of that float. Today, the average trading volume of NTLA was 1.12M shares.
NTLA’s Market Performance
NTLA stocks went up by 24.02% for the week, with a monthly jump of 7.27% and a quarterly performance of -27.73%, while its annual performance rate touched -39.28%. The volatility ratio for the week stands at 10.75% while the volatility levels for the past 30 days are set at 9.42% for Intellia Therapeutics Inc. The simple moving average for the period of the last 20 days is 14.05% for NTLA stocks with a simple moving average of -46.08% for the last 200 days.
Analysts’ Opinion of NTLA
Many brokerage firms have already submitted their reports for NTLA stocks, with BMO Capital Markets repeating the rating for NTLA by listing it as a “Market Perform.” The predicted price for NTLA in the upcoming period, according to BMO Capital Markets is $54 based on the research report published on June 17th of the current year 2022.
BofA Securities, on the other hand, stated in their research note that they expect to see NTLA reach a price target of $70. The rating they have provided for NTLA stocks is “Buy” according to the report published on June 16th, 2022.
Credit Suisse gave a rating of “Outperform” to NTLA, setting the target price at $100 in the report published on April 28th of the current year.
NTLA Trading at 5.07% from the 50-Day Moving Average
After a stumble in the market that brought NTLA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.96% of loss for the given period.
Volatility was left at 9.42%, however, over the last 30 days, the volatility rate increased by 10.75%, as shares surge +18.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.69% lower at present.
During the last 5 trading sessions, NTLA rose by +24.02%, which changed the moving average for the period of 200-days by -68.91% in comparison to the 20-day moving average, which settled at $44.90. In addition, Intellia Therapeutics Inc. saw -57.07% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at NTLA starting from LEONARD JOHN M, who sale 2,493 shares at the price of $112.25 back on Jan 01. After this action, LEONARD JOHN M now owns 724,660 shares of Intellia Therapeutics Inc., valued at $279,852 using the latest closing price.
Goddard Glenn, the EVP, Chief Financial Officer of Intellia Therapeutics Inc., sale 1,013 shares at $112.24 during a trade that took place back on Jan 01, which means that Goddard Glenn is holding 2,049 shares at $113,699 based on the most recent closing price.
Stock Fundamentals for NTLA
Current profitability levels for the company are sitting at:
- -810.37 for the present operating margin
- +79.15 for the gross margin
The net margin for Intellia Therapeutics Inc. stands at -810.49. Equity return is now at value -41.00, with -32.70 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 6.11.